Dr. Thom Tulip Joins Microvascular Therapeutics Inc. as Chief Business Officer
February 10, 2024, Tucson, AZ — Microvascular Therapeutics Inc. (MVT), a leading biotech company in the development of innovative microbubbles for therapeutic ultrasound applications, is pleased to announce the appointment of Dr. Thom Tulip as their new Chief Business Officer. Dr. Tulip will spearhead fundraising efforts to drive MVT’s advanced technologies into the marketplace.
Experience and Expertise of Dr. Thom Tulip
Dr. Tulip brings a wealth of experience in the successful development and commercialization of imaging agents to MVT. With a proven track record of contributing to the approval of 15 new chemical entities and expanding treatment indications, Dr. Tulip’s knowledge perfectly aligns with MVT’s goal of introducing the revolutionary imaging agent, MVT-100, to the market. His industry insights and extensive connections are poised to accelerate MVT’s growth trajectory.
Testimonials from MVT Leadership
“We are excited to have Thom Tulip on board. With his background at DuPont, Thom will play a crucial role in advancing MVT-100 towards NDA approval,” said Dr. Evan Unger, Founder, and Chairman of the board. “In just one month, Dr. Tulip’s input has already enhanced our strategic approach, and his vast industry network will undoubtedly drive MVT’s success. His addition to the team is a significant asset,” added Dr. Emmanuelle Meuillet, Chief Operating and Scientific Officer.
Dr. Tulip’s Role in MVT’s Transition
As MVT evolves from a research-focused entity to a clinical-stage biopharmaceutical company, Dr. Tulip’s wealth of experience and expertise will be pivotal in ensuring a smooth and successful transition.
Contact Information
For more details about Microvascular Therapeutics and their new Chief Business Officer, please reach out to:
Company Contact:
Microvascular Therapeutics
Dr. Evan C. Unger, Chairman BOD
Dr. Emmanuelle Meuillet, COO/CSO
Investor Contact:
Bryan Unger
T: 520.907.3537
E: b.unger@mvtpharma.com
About Microvascular Therapeutics (MVT)
Microvascular Therapeutics is a biotechnology company headquartered in Tucson, Arizona, specializing in microbubble and nanobubble technology. MVT’s mission is to advance diagnostic ultrasound by developing next-generation contrast agents for the diagnosis and treatment of various diseases, including vascular conditions. MVT has introduced a patented microbubble platform for creating agents for molecular imaging and image-guided therapy. Learn more at [www.mvtpharma.com](http://www.mvtpharma.com).
Contact Information for Microvascular Therapeutics:
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Categories
- Personnel Announcements